Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

• Status: Not yet recruiting
• Trial end date: 2026-10-01

Summary

The purpose of this research is to investigate the activity and safety of the combination of gemcitabine plus nab-paclitaxel and sintilimab as neoadjuvant therapy in treating patients with resectable and borderline resectable pancreatic cancer.

The drugs involved in this study are:

• Sintilimab

• Nab-paclitaxel

• Gemcitabine

• Phase: Phase 2

Details

• Lead Sponsor: Shanghai Zhongshan Hospital
• Collaborator: Fudan University
• Treatments: Gemcitabine; Paclitaxel